Edesa Biotech (NASDAQ: EDSA) just received clearance from the FDA to expand its Phase 2 clinical trial of EB06, an experimental treatment for vitiligo, into the United States.

‍

If you’re unfamiliar, vitiligo is an autoimmune disease that causes patches of skin to lose their natural color. It develops when the immune system mistakenly attacks the cells responsible for producing melanin, the pigment that gives skin its color.

‍

Although treatments are available, including prescription creams and light therapy, there are currently no FDA-approved systemic medications specifically for vitiligo. These would be treatments that work throughout the body rather than being applied directly to affected skin.

‍

Edesa hopes EB06 can help change that.

‍

How EB06 works

‍

EB06 is an experimental antibody treatment designed to block a protein called CXCL10, which helps direct immune cells toward areas of inflammation.

‍

In people with vitiligo, this protein is believed to contribute to the destruction of melanocytes, the cells that produce skin pigment.

‍

By blocking CXCL10, researchers hope to interrupt the immune response responsible for pigment loss, potentially allowing the skin to regain some of its natural color.

‍

The treatment has already been evaluated in 65 participants across three earlier clinical studies. According to Edesa, those studies demonstrated biological activity consistent with the drug's intended mechanism, and the treatment was generally safe and well tolerated.

‍

The next step

‍

Edesa's ongoing Phase 2 trial will enroll up to 80 adults with moderate-to-severe nonsegmental vitiligo, the most common form of the disease.

‍

Participants will receive either EB06 or a placebo every two weeks through week 22. Researchers will then measure changes in facial skin pigmentation at week 28 to determine whether the treatment produces meaningful improvements.

‍

Patient recruitment is already underway in Canada, with U.S. enrollment expected to begin in the first quarter of 2027.

‍

Edesa anticipates reporting initial results in the fourth quarter of 2027.

‍

For a small biotechnology company, positive Phase 2 results could provide important evidence supporting further development of EB06. They could also strengthen the company's position as it considers the financing and partnerships needed for larger clinical trials.

‍